Skip to main content

Table 4 Predictors of Physical health MSQoL-54 scales by IFN-β treatment (Multivariate hierarchical analysis)

From: Influence of Interferon beta treatment on quality of life in multiple sclerosis patients

  Energy Health perceptions Physical function Role limitation physical Bodily pain Social function
Effect β p β p β p β p β p β p
Intercept* 45.11 <.0001 44.67 <.0001 69.40 <.0001 71.72 <.0001 74.23 <.0001 72.54 <.0001
Age at inclusion -0.12 0.36 0.06 0.68 -0.4 0.01 -0.60 0.03 -0.36 0.04 0.06 0.66
Gender (Male vs. Female) -0.51 0.84 2.00 0.52 1.07 0.75 -17.3 0.003 3.74 0.31 -0.32 0.90
Disease duration -0.02 0.92 -0.36 0.08 0.10 0.64 0.19 0.60 -0.38 0.12 -0.30 0.10
Disease course (SP vs. RR) 9.54 0.03 7.35 0.16 -8.44 0.12 8.77 0.34 17.33 0.004 8.65 0.06
Relapse rate 2-yrs before study entry 0.37 0.90 -2.01 0.58 0.70 0.86 1.39 0.83 -0.20 0.96 3.76 0.24
EDSS -2.33 0.06 -3.54 0.02 -8.44 <.0001 -4.69 0.09 -2.82 0.11 -2.65 0.05
BDI -1.16 <.0001 -0.26 0.20 0.25 0.26 -0.92 0.01 0.22 0.36 -0.66 0.0004
FSS -4.80 <.0001 -6.8 <.0001 -8.69 <.0001 -10.0 <.0001 -9.74 <.0001 -6.72 <.0001
MMSE-c -0.19 0.71 -0.43 0.46 0.05 0.94 -1.90 0.10 0.02 0.98 -0.30 0.57
IFN-β treatment (Yes vs No) 1.43 0.65 3.56 0.32 1.20 0.77 5.03 0.50 4.54 0.32 0.23 0.94
Relapse rate change after 2-yrs 4.96 0.17 2.40 0.61 3.76 0.20 -2.71 0.69 2.96 0.54 6.77 0.08
EDSS change after 2-yrs -0.11 0.95 -1.49 0.54 -4.54 0.003 0.59 0.86 0.70 0.77 -2.72 0.16
BDI change after 2-yrs -0.67 0.0005 -0.48 0.05 -0.14 0.37 -1.59 <.0001 -0.82 0.002 -0.67 0.001
FSS change after 2-yrs -5.20 <.0001 -4.89 0.001 -4.65 <.0001 -4.75 0.03 -5.98 0.0001 -4.39 0.0003
MMSE-c change after 2-yrs -1.09 0.15 0.20 0.84 -0.10 0.87 -3.04 0.04 -0.64 0.53 0.18 0.81
Time** 8.67 0.004 3.36 0.37 -4.84 0.05 -1.00 0.86 -1.81 0.65 0.64 0.84
Time × IFN-β treatment (Yes vs No) -0.76 0.86 -1.72 0.74 -6.15 0.07 -2.54 0.77 3.82 0.50 -1.73 0.69
  1. *Intercept value represents the baseline mean score for reference group (Untreated)
  2. **Time value represents the mean score change for reference group (Untreated) after 2 years of follow-up